Novo Nordisk stock faces an FDA delay as Q2 sales grow 7 percent

Published on 10/04/2026 at 14:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock faces an FDA delay after the October 2 denecimig update. Q2 adjusted sales rose 7 percent at constant exchange rates, while 2026 guidance stays at 0% to -6%.

Forscherin im Laborkittel an Pipette, Schwarzweiß-Reportagefoto, Labor — Novo Nordisk A/S (DK0062498333): Forscherin im Labor-Kittel bedient Pipette in dokumentarischem Schwarzweiß-Reportagefoto, Illustration mit AI erstellt.

Novo Nordisk (ISIN DK0062498333) faces a delayed U.S. regulatory decision for denecimig after the FDA extended its review, while Q2 adjusted sales reached DKK 78.5 billion, up 7 percent at constant exchange rates. The October 2, 2026 company update keeps the 2026 outlook unchanged and points to a potential U.S. launch in the first half of 2027, according to FinanzNachrichten.de.

FDA review pushes launch into 2027

The extended review centers on remediation work at a manufacturing facility. The FDA feedback did not identify deficiencies in denecimig clinical efficacy or safety data, and the company said the facility issue does not affect other marketed products, according to FinanzNachrichten.de on October 2, 2026. The regulatory delay therefore shifts the commercial milestone toward the first half of 2027 rather than removing the program from the pipeline.

The denecimig update arrives after Novo Nordisk agreed to pay up to USD 2.6 billion for rights to HRS-1596, an experimental once-weekly obesity pill from Jiangsu Hengrui Pharmaceuticals. The deal includes a USD 300 million upfront payment and up to USD 2.3 billion in development, regulatory and commercial milestones, according to Reuters on September 29, 2026.

Q2 sales grew 7 percent

Novo Nordisk's Q2 adjusted operating profit rose 11 percent at constant exchange rates, reaching DKK 33.4 billion. The improvement came with a lower adjusted gross margin of 78.2 percent versus 82.7 percent in Q2 2025, reflecting lower realized prices and manufacturing-capacity costs, according to Yahoo Finance.

The operating mix remains important. Obesity-care sales increased 16 percent in Q2, while international GLP-1 sales grew 13 percent, showing that volume expansion continues even as pricing weighs on margins. The company also said adjusted sales growth for 2026 is expected at 0% to -6% at constant exchange rates, with adjusted operating profit growth in the same range.

Guidance stays at 0% to -6%

The next major checkpoint is Q3 reporting on November 3, 2026. That date is listed in the Novo Nordisk calendar published by MarketScreener.

Novo Nordisk stock faces a key test

Novo Nordisk stock enters the next reporting phase with DKK 78.5 billion of Q2 adjusted sales, an 11 percent adjusted operating-profit increase and a regulatory timetable extending into 2027. For investors, the central tension is clear: volume growth remains measurable, while pricing pressure, manufacturing execution and pipeline timing shape the earnings path.